Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Stock Chart & Stats
$13.68
-$0.43(-1.58%)
At close: 4:00 PM EST
$13.68
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$11.48 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)939.56K
Market Cap
$428.05M
Enterprise Value$386.21M
Total Cash (Recent Filing)$202.17M
Total Debt (Recent Filing)$461.00K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 25, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding31,289,968
10 Day Avg. Volume698,603
30 Day Avg. Volume939,561
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)3.01
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue22.07
Enterprise Value/Gross Profit22.27
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$53.83Price Target Upside293.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$51.08M
Bulls Say, Bears Say
Bulls Say
Commercial TractionStrong early prescriber engagement and encouraging prescription uptake for VIZZ, with many eye care professionals writing prescriptions and growing repeat prescribing, supports potential revenue momentum.
Direct-to-consumer MarketingA planned direct-to-consumer campaign featuring a high-profile spokesperson is designed to boost awareness and drive patient demand, using digital insights to optimize advertising for VIZZ.
International Distribution DealsAn exclusive distribution agreement covering major Middle East markets provides upfront and milestone payments plus revenue sharing, expanding VIZZ's commercial footprint and diversifying revenue sources.
Bears Say
Competitive PressureA competitor securing financing to support a commercial launch strengthens rival market entry and could intensify promotional competition in the presbyopia market, challenging VIZZ uptake.
Safety Monitoring RiskReports of retinal tears and related adverse events create a monitoring risk that could slow prescribing if perceived as drug-related, despite indications these events may align with background rates.
Slower Market Ramp And ForecastsMarket build efforts progressing slower than assumed and a more conservative view on the shift from online pharmacy to broad retail availability have prompted analysts to reduce peak sales expectations and lower price objectives.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $11.48 and its highest was $50.40 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $428.05M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 21 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.102.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.91.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 31,289,968 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went down -23.458%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.83 (293.49% Upside)
$53.83 (293.49% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 763.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.33%
12-Months-Change
Fundamentals
Return on Equity
-28.78%
Trailing 12-Months
Asset Growth
-5.94%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for LENZ, highlighted by the successful early launch of VIZZ and significant financial backing. While there were minor issues with transient side effects and initial retail availability, the overall sentiment was bolstered by strong prescription metrics, high awareness among doctors, and strategic partnerships.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$53.83
▲(293.49% Upside)
Technical Analysis
Ownership Overview
15.14% Insiders
18.36% Mutual Funds
32.01% Other Institutional Investors
26.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---